

## DORSET MEDICINES ADVISORY GROUP

### COMMISSIONING STATEMENT ON THE USE OF VORTIOXETINE FOR TREATING MAJOR DEPRESSIVE EPISODES (TA367)

<b>SUMMARY</b> NHS Dorset Clinical Commissioning Group commissions the use of vortioxetine as an option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode in accordance with NICE TA367.	
<b>BACKGROUND</b>	<p>Vortioxetine (Brintellix®) is indicated for the treatment of major depressive episodes in adults. Vortioxetine is an antidepressant that is thought to exhibit its clinical effect through direct modulation of receptor activity and inhibition of the serotonin transporter.</p> <p>The starting and recommended dose is 10 mg vortioxetine once daily in adults less than 65 years of age. Depending on individual patient response, the dose may be increased to a maximum of 20 mg vortioxetine once daily or decreased to a minimum of 5 mg vortioxetine once daily.</p> <p>After the depressive symptoms resolve, treatment for at least 6 months is recommended for consolidation of the antidepressive response.</p> <p>Patients treated with vortioxetine can abruptly stop taking the medicinal product without the need for a gradual reduction in dose.</p> <p>The lowest effective dose of 5 mg vortioxetine once daily should always be used as the starting dose in patients ≥ 65 years of age. Caution is advised when treating patients ≥ 65 years of age with doses higher than 10 mg vortioxetine once daily for which data are limited</p>
<b>RELEVANT NICE GUIDANCE</b>	<p>NICE TA367 states:</p> <ul style="list-style-type: none"><li>• Vortioxetine is recommended as an option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode.</li></ul>
<b>FORMULARY STATUS</b>	Amber, specialist initiation, no shared care guideline
<b>PBR STATUS</b>	Included in tariff
<b>COMMISSIONING IMPLICATIONS</b>	An alternative antidepressant option to existing treatments. Higher acquisition cost than alternative options. More favourable side effect profile
<b>RELEVANT CLINICAL WORKING GROUP</b>	Mental health
<b>PATIENT PATHWAY IMPLICATIONS</b>	It should only be prescribed after other antidepressant treatment options have been exhausted. Due to these limitations, it should only be Specialist Initiated only.

<b>SUMMARY OF EVIDENCE TO SUPPORT FORMULARY STATUS</b>	<p>Summarised in 'consideration of the evidence' section of <a href="#">TA367</a> and proposal form.</p> <p>The summary of product characteristics lists the following 'common' and 'very common' adverse reactions for vortioxetine: abnormal dreams, constipation, diarrhoea, dizziness, itching, nausea and vomiting.</p>																		
<b>ASSESSMENT OF COST IMPLICATIONS</b>	<p>All strengths for one month £27.72. other antidepressants that may be prescribed as '3<sup>rd</sup> line' treatments :-</p> <table border="1" data-bbox="507 488 1503 712"> <thead> <tr> <th>'3<sup>rd</sup> line' antidepressant</th> <th>Strength</th> <th>Cost for 28 day</th> </tr> </thead> <tbody> <tr> <td>Vortioxetine</td> <td>All strengths</td> <td>27.72</td> </tr> <tr> <td>Venlafaxine</td> <td>75mg bd</td> <td>2.98</td> </tr> <tr> <td>Amitriptyline</td> <td>100mg on</td> <td>2.36</td> </tr> <tr> <td>Duloxetine</td> <td>60mg om</td> <td>26.65</td> </tr> <tr> <td>Moclobemide</td> <td>150mg om</td> <td>21.84</td> </tr> </tbody> </table> <p>Prices from eBNF 15.12.15 and TA367  NICE submission claims that the more favourable side effect profile will result in reduced GP visits due to side effect management. This was calculated as 0.3 GP visits per year.</p>	'3 <sup>rd</sup> line' antidepressant	Strength	Cost for 28 day	Vortioxetine	All strengths	27.72	Venlafaxine	75mg bd	2.98	Amitriptyline	100mg on	2.36	Duloxetine	60mg om	26.65	Moclobemide	150mg om	21.84
'3 <sup>rd</sup> line' antidepressant	Strength	Cost for 28 day																	
Vortioxetine	All strengths	27.72																	
Venlafaxine	75mg bd	2.98																	
Amitriptyline	100mg on	2.36																	
Duloxetine	60mg om	26.65																	
Moclobemide	150mg om	21.84																	
<b>REFERENCES</b>	<p><a href="#">NICE TA367</a>. Vortioxetine for treating major depressive episodes</p> <p><a href="#">Summary of product characteristics</a>. Vortioxetine, Brintellix® tablets 5, 10 and 20mg. Lundbeck. Accessed 5<sup>th</sup> January 2016.</p>																		
<b>Date</b>	January 2016																		
<b>Review date</b>	January 2018 or before in the light of new information																		
<b>Contact</b>	Michelle Trevett, Senior Pharmacist, NHS Dorset CCG																		